Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
Monte Rosa Therapeutics (Nasdaq: GLUE) has appointed Dr. Eric A. Hughes to its Board of Directors. Dr. Hughes currently serves as Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceuticals. He brings extensive experience in biopharmaceutical industry leadership, having previously held senior positions at Vertex Pharmaceuticals, Novartis, and Bristol Myers Squibb.
Dr. Hughes's expertise includes building R&D organizations and developing therapeutics across multiple disease areas, particularly in immunology and inflammation. His appointment aligns with Monte Rosa's expansion into these therapeutic areas and their continued development of molecular glue degrader (MGD)-based medicines through their QuEEN™ discovery engine.
Monte Rosa Therapeutics (Nasdaq: GLUE) ha nominato il Dr. Eric A. Hughes nel suo Consiglio di Amministrazione. Il Dr. Hughes attualmente ricopre il ruolo di Vice Presidente Esecutivo, R&D Globale e Direttore Medico di Teva Pharmaceuticals. Porta con sé un'ampia esperienza nella leadership del settore biofarmaceutico, avendo precedentemente ricoperto posizioni di alto livello in Vertex Pharmaceuticals, Novartis e Bristol Myers Squibb.
La competenza del Dr. Hughes include la creazione di organizzazioni di R&D e lo sviluppo di terapeutiche in diverse aree terapeutiche, in particolare nell'immunologia e nell'infiammazione. La sua nomina è in linea con l'espansione di Monte Rosa in queste aree terapeutiche e con il continuo sviluppo di medicinali basati su degradatori di collante molecolare (MGD) attraverso il loro motore di scoperta QuEEN™.
Monte Rosa Therapeutics (Nasdaq: GLUE) ha nombrado al Dr. Eric A. Hughes en su Junta Directiva. El Dr. Hughes actualmente se desempeña como Vicepresidente Ejecutivo, I+D Global y Director Médico de Teva Pharmaceuticals. Aporta una amplia experiencia en liderazgo en la industria biofarmacéutica, habiendo ocupado anteriormente posiciones de alto nivel en Vertex Pharmaceuticals, Novartis y Bristol Myers Squibb.
La experiencia del Dr. Hughes incluye la construcción de organizaciones de I+D y el desarrollo de terapias en diversas áreas de enfermedad, particularmente en inmunología e inflamación. Su nombramiento se alinea con la expansión de Monte Rosa en estas áreas terapéuticas y con su desarrollo continuo de medicamentos basados en degradadores de adhesivo molecular (MGD) a través de su motor de descubrimiento QuEEN™.
몬테 로사 테라퓨틱스 (Nasdaq: GLUE)는 이사회에 에릭 A. 휴즈 박사를 임명했습니다. 휴즈 박사는 현재 테바 제약의 글로벌 R&D 부사장 및 최고 의학 책임자로 재직 중입니다. 그는 버텍스 제약, 노바티스, 브리스톨 마이어스 스퀴브에서 고위직을 역임하며 생명공학 산업 리더십에 대한 풍부한 경험을 가지고 있습니다.
휴즈 박사의 전문 분야에는 R&D 조직 구축과 여러 질병 영역에서의 치료제 개발이 포함되어 있으며, 특히 면역학과 염증에 중점을 두고 있습니다. 그의 임명은 몬테 로사가 이러한 치료 분야로의 확장을 지속하고 퀸™ 발견 엔진을 통해 분자 접착제 분해제(MGD) 기반 약물 개발을 계속하는 것과 일치합니다.
Monte Rosa Therapeutics (Nasdaq: GLUE) a nommé le Dr. Eric A. Hughes à son conseil d'administration. Le Dr. Hughes occupe actuellement le poste de Vice-Président Exécutif, R&D Mondiale et Directeur Médical chez Teva Pharmaceuticals. Il apporte une vaste expérience en leadership dans l'industrie biopharmaceutique, ayant précédemment occupé des postes de haut niveau chez Vertex Pharmaceuticals, Novartis et Bristol Myers Squibb.
Les compétences du Dr. Hughes comprennent la création d'organisations de R&D et le développement de thérapeutiques dans plusieurs domaines de maladies, en particulier en immunologie et en inflammation. Sa nomination s'inscrit dans le cadre de l'expansion de Monte Rosa dans ces domaines thérapeutiques et de leur développement continu de médicaments basés sur des dégradants de colle moléculaire (MGD) à travers leur moteur de découverte QuEEN™.
Monte Rosa Therapeutics (Nasdaq: GLUE) hat Dr. Eric A. Hughes in seinen Aufsichtsrat berufen. Dr. Hughes ist derzeit als Executive Vice President, Global R&D und Chief Medical Officer bei Teva Pharmaceuticals tätig. Er bringt umfassende Erfahrungen in der Führung der biopharmazeutischen Branche mit, da er zuvor leitende Positionen bei Vertex Pharmaceuticals, Novartis und Bristol Myers Squibb innehatte.
Die Expertise von Dr. Hughes umfasst den Aufbau von R&D-Organisationen und die Entwicklung von Therapeutika in mehreren Krankheitsbereichen, insbesondere in der Immunologie und Entzündung. Seine Ernennung steht im Einklang mit der Expansion von Monte Rosa in diese therapeutischen Bereiche und deren kontinuierlicher Entwicklung von Medikamenten auf der Basis von molekularen Kleberabbauern (MGD) durch ihre Entdeckungsplattform QuEEN™.
- Addition of experienced R&D executive with expertise in immunology and inflammation, aligned with company's expansion plans
- Strengthened board expertise in clinical development and drug commercialization
- Enhanced leadership in molecular glue degrader development through experienced pharmaceutical executive
- None.
BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes is currently Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceuticals and brings decades of biopharmaceutical industry leadership experience to Monte Rosa.
“I am very excited to welcome Dr. Eric Hughes to the Monte Rosa Board of Directors,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “Eric brings extensive experience building and leading highly productive R&D organizations and shepherding important new therapeutics through clinical development to improve the lives of patients. In light of our expansion into new disease areas, in particular immunology and inflammation, he will be a tremendous asset to our organization as we continue to advance and expand our pipeline of differentiated molecular glue degrader-based medicines.”
Dr. Hughes currently serves as Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceuticals. Prior to joining Teva, he was Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals. Previously, he was Global Development Unit Head for Immunology, Hepatology and Dermatology at Novartis and held several executive and senior positions at Bristol Myers Squibb, including Head of Virology, Fibrotic Diseases, Genetically Defined Diseases, Autoimmunity, and Cardiology Discovery Medicine, Exploratory Clinical & Translational Research. During the COVID-19 pandemic, Dr. Hughes served as Co-Chair of the Therapeutics Clinical Working Group for the Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership at the National Institutes of Health. He received his M.D. and Ph.D. from Yale School of Medicine.
"Monte Rosa has truly become the leader in the burgeoning space of molecular glue degraders and I’m honored to join the Board. The depth of the pipeline and the recent program advancements in new therapeutic areas are notable – evidence that the QuEEN™ discovery engine can address a broad range of targets and therapeutic areas,” said Dr. Hughes. “I’m particularly inspired by the company’s focus on tackling undruggable targets, which offers immense potential for transforming patient care. I look forward to supporting Monte Rosa and their goal to deliver innovative therapies that make a meaningful difference for patients."
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
What is the significance of Dr. Eric Hughes joining Monte Rosa Therapeutics (GLUE) board?
What is Dr. Eric Hughes's current role outside of Monte Rosa Therapeutics (GLUE)?
How does Dr. Hughes's appointment align with Monte Rosa's (GLUE) strategic direction?
What is Monte Rosa Therapeutics' (GLUE) main technological focus?
